Repligen Corporation RGEN
Composite 47/100; the shares have moved about 52% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 13/100 — a strong mark against it.
Balance-sheet strength ranks 78/100 — a strong point in its favour. Momentum ranks 72/100 — a moderate point in its favour.
Valuation ranks 13/100 — a strong mark against it. Quality ranks 39/100 — a slight mark against it. Growth ranks 41/100 — a slight mark against it.
What the company does Repligen Corporation develops and commercializes bioprocessing technologies and systems for drug development and manufacturing. Its portfolio includes hollow fiber consumables, chromatography systems, real-time monitoring tools, and filtration products used in upstream and downstream biologic drug production.
Key financials Repligen reports gross margins of 53.1%, operating margins of 8.9%, and net margins of 6.7%. Revenue grew 14.8% year-over-year, while EPS surged 47.9%. The company maintains a strong balance sheet with a debt-to-equity ratio of 0.33 and a current ratio of 9.05, though interest coverage is 1.75.
Stock health The stock shows mixed momentum: up 20.18% over 3 months, down -9.07% over 6 months, and up 15.74% over 12 months. It is -19.11% below its 52-week high, with an RSI(14) of 53.40 indicating neutral momentum.
Price vs fair value The stock trades at a PREMIUM of 65.70% versus our fair-value estimate of 48.74 and at a discount of 30.45% versus the analyst 12-month target of 185.47. - Q2 2026 earnings beat and raised guidance fueled recent price strength (Zacks, StockStory). - Analysts highlight potential 25.72% upside based on recent performance (Zacks). - M&A discussions and earnings call optimism supported sentiment (Simply Wall St., GuruFocus.com).
Looking forward Forward P/E of 66.67 and PEG of 0.57 suggest high growth expectations. The company’s strong revenue and EPS growth, combined with robust margins and balance sheet metrics, underpin its premium valuation. However, elevated multiples and a weak quality score (40.4) warrant caution.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.